DocWire News Editors

DocwireNews

<a href="https://www.docwirenews.com/abstracts/venetoclax-and-obinutuzumab-in-patients-with-cll-and-coexisting-conditions/">Research</a> presented by Dr. Kirsten Fischer at the <a href="https://www.docwirenews.com/european-hematology-association-24th-congress/">24th&nbsp;Congress of European Hematology Association (EHA)</a> in Amsterdam on June 14 shows the efficacy of venetoclax (VENCLEXTA) and obinutuzumab (GAZYVA) in treating patients with <a href="https://www.docwirenews.com/conference-coverage/2019-hopa/treatment-standards-patients-chronic-lymphocytic-leukemia/">chronic lymphocytic leukemia (CLL)</a>. This work supports the use of such treatment as a first-line therapy in patients with CLL and co-existing conditions.<a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/ibrutinib-venetoclax-first-line/">Venetoclax</a> is a selective inhibitor of BCL2, a protein responsible for regulating cell death that is overexpressed in CLL cells. By inhibiting this protein, venetoclax functions to rapidly induce apoptosis in these malignant cells. Obinutuzumab is an anti-CD20 monoclonal antibody that can bind and destroy CLL cells.With pre-clinical data suggesting a maximal additive effect for venetoclax when used in concert with obinutuzumab, this study was conducted to test the efficacy of such treatment in elderly patients with previously untreated CLL. Current treatments for CLL patients are continuous and indefinite targeted therapy or fixed duration chemoimmunotherapy. Venetoclax-obinutuzumab treatment presents as a new fixed duration targeted treatment regimen that could potentially bolster CLL care.This CLL14 study was created by the German CLL Study Group to evaluate a non-chemotherapeutic fixed-duration treatment consisting of venetoclax and obinutuzumab. The efficacy of this treatment was compared to that of a standard chemoimmunotherapy treatment with chlorambucil and obinutuzumab in untreated patients with CLL and other comorbidities.When presenting these findings at the <a href="https://www.docwirenews.com/european-hematology-association-24th-congress/">24th EHA Congress</a>, Fischer emphasized data on minimal residual disease (MRD) from the CLL14 study. It was found that the use of venetoclax and obinutuzumab yielded better outcomes than chlorambucil and obinutuzumab did regarding progression free survival. 88% of the patients treated with venetoclax-obinutuzumab showed no disease progression two years after treatment, compared to only 64% of those treated with chlorambucil-obinutuzumab.In addition, 76% of the patients treated with venetoclax-obinutuzumab showed no MRD in the blood three months after treatment, compared to 35% in the standard group.The researchers concluded that venetoclax&ndash;obinutuzumab fixed-duration targeted therapy can safely be used in elderly CLL patients with co-existing conditions. Such treatment was superior to chlorambucil-obinutuzumab treatment in progression free survival, overall response rate, complete response rate, MRD negative responses, and in all relevant subgroups including IGVH unmutated, del(17p) or TP53 mutated patients. The team also noted that venetoclax&ndash;obinutuzumab treatment could present as an alternative to continuous indefinite BTK inhibitor treatment.The presenters also noted that this approach yielded the highest rate of MRD negative results observed in a such a study thus far. This work helped venetoclax&ndash;obinutuzumab treatment receive Breakthrough Therapy Designation by the FDA, a review under the Real-Time Oncology Review Pilot Program, and approval for treatment of previously untreated CLL/small lymphocytic lymphoma patients this past May.<blockquote class="twitter-tweet">
Penultimate presentation in the <a href="https://twitter.com/hashtag/CLL?src=hash&amp;ref_src=twsrc%5Etfw">#CLL</a> session argues that ibrutinib and venetoclax together has the potential to help people achieve MRD negativity, and patients only need continue ibrutinib if they do not respond. <a href="https://twitter.com/hashtag/EHA24?src=hash&amp;ref_src=twsrc%5Etfw">#EHA24</a> <a href="https://twitter.com/LeukaemiaCareUK?ref_src=twsrc%5Etfw">@LeukaemiaCareUK</a> <a href="https://t.co/FOZex0VmWX">pic.twitter.com/FOZex0VmWX</a>
&mdash; Charlotte Martin (@scicommchar) <a href="https://twitter.com/scicommchar/status/1139481013137092608?ref_src=twsrc%5Etfw">June 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Success of Venetoclax and Obinutuzumab Use in Patients with CLL

European Society of Hematology 2019

Research presented by Dr. Kirsten Fischer at the 24th Congress of European Hematology Association (EHA) in Amsterdam on June 14 shows the efficacy of venetoclax (VENCLEXTA) ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe